Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease

International Journal of Neuropsychopharmacology

Volumn 2, Issue 1, 1999, Pages 59-66

  Cummings, Jeffrey L ^a   Fairbanks, Lynn ^a   Masterman, Donna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Behavioural responses; Clinical trials; Symptom analysis

Indexed keywords

EID: 0002312637     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001340     Document Type: Article

References (49)

1. Albert SM, Sano M, Marder K, Jacobs DM, Brandt J, Albert M, Stern Y (1997). participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 49, 38-43.
2. Alexopoulus GS, Abrams RC, Young RC (1988). Cornell scale for depression in dementia. Biological Psychiatry 23, 271-284.
3. Binetti G, Mega MS, Magni E, Padovani A, Rozzini L, Lussignoli G, Bianchetti A, Trabucchi M, Cummings J. (1998). Behavioral disorders in Alzheimer's disease: a transcultural perspective. Archives of Neurology 55, 539-544.
4. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997). Effects of xanomeline, a selective receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Archives of Neurology 4, 46-473.
5. Chui HC, Lyness SA, Sobel E, Schneider LS (1994). Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Archives of Neurology 51, 676-681.
6. Cohen-Mansfield J, Billig N (1986). Agitated behaviors in the elderly. I. A conceptual review. Journal of the American Geriatrics Society 844, 711-721.
7. Cummings JL (1996a). Theories behind existing scales for rating behavior in dementia. International Psychogeriatrics 8, 293-300.
8. Cummings JL (1996b). General overviews. Neuropsychiatric assessment and intervention in Alzheimer's disease. International Psychogeriatrics 8 (Suppl. 1), 25-30.
9. Cummings JL, Cyrus PA, Bieber F, Orazem J, Mas J, Gulanski B. (1988). The effect of metrifonate on the cognitive, functional and behavioral symptoms of Alzheimer's disease patients (Abstract). Presented at the American Association of Geriatric Psychiatry Annual Meeting, San Diego, CA, 10 March, 1998.
10. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
11. Devanand DP, Jacobs DM, Tang MX, Castillo-Castaneda CD, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y (1997). The course of psychopathic features in mild to moderate Alzheimer disease. Archives of General Psychiatry 54, 257-263.
12. Everitt BS (1998). Analysis of longitudinal data. British Journal of Psychiatry 172, 7-10.
13. Gershon S, Ferris SH, Kennedy JS, Kurtz NM, Overall JE, Pollock BG, Reisberg B, Whitehouse PJ (1994). Methods for the evaluation of pharmacologic agents in the treatment of cognitive and other deficits in dementia. In: Prien RF, Robinson DS (Eds.), Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines (pp. 467-499). New York: Raven Press.
14. Goodman LA (1978). Analyzing Qualitative/Categorical Data. Cambridge, MA, Addison-Wesley.
15. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
16. Huck SW, Cormier WH, Bounds WG, Jr (1974). Reading Statistics and Research. New York: Harper & Row.
17. Kaufer DI, Cummings JL, Christine D (1996). Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. Journal of Geriatric Psychiatry and Neurology 9, 1-6.
18. Kaufer DI, Cummings JL, Christine D (1998b). Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. Journal of Neuropsychiatry and Clinical Neurosciences 10, 55-63.
19. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky ST (1998a). Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. Journal of the American Geriatrics Society 46, 210-215.
20. Knopman DS, Knapp MJ, Gracon SI, Davis CS (1994). The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 44, 2315-2321.
21. Lavori PW, Laska EM, Uhlenhuth EH (1994). Statistical issues for the clinical evaluation of psychotropic drugs. In: Prien RF, Robinson DS (Eds.), Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines (pp 139-160). New York: Raven Press.
22. Levy M, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A (1996a). Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. American Journal of Psychiatry 153, 1438-1443.
23. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I (1998). Apathy is not depression. Journal of Neuropsychiatry and Clinical Neurosciences 10, 314-319.
24. Levy M, Miller BL, Cummings JL, Fairbanks LA, Craig A (1996b). Alzheimer disease and frontotemporal dementias: behavioral distinctions. Archives of Neurology 53, 687-690.
25. Litvan I, Cummings JL, Mega M. (In Press). Neuropsychiatric aspects of corticobasal degeneration. Journal of Neurological and Neurosurgical Psychiatry.
26. Litvan I, Mega M, Cummings JL, Fairbanks L. (1996). Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 47, 1184-1189.
27. Matthews DE, Farewell VT (1988). Using and Understanding Medical Statistics (2nd, revised edition). Basel: Karger.
28. Mega MS, Cummings JL, Fiorello T, Gornbein J (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135.
29. 99m Tc-HMPAO-SPECT are associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. Neurology 50, A250 (Abstract).
30. Mohs RC, Knopman D, Petersen RC, Ferris SH, Emesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thai LJ, and the Alzheimer's Disease Cooperative Study (1997). Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Disease and Associated Disorders 11 (Suppl. 2), S13-S21.
31. Morris JC, Cyrus PA, Orazem J, Mas J., Bieber F, Ruzicka BB, Gulanski B (1998). Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 50, 1222-1230.
32. Mortimer JA, Ebbitt B, Jun S-P, Finch MD (1992). Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 42, 1689-1696.
33. O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA (1992). Incontinence and troublesome behaviors predict institutionalization in dementia. Journal of Geriatric Psychiatry and Neurology 5, 45-52.
34. Patterson MB, Mack JL, Mackell JA, Thomas R, Tariot P, Weiner M, Whitehouse PJ, and the Alzheimer's Disease Cooperative Study (1997). A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. Alzheimer Disease and Associated Disorders 11 (Suppl. 2), S40-S44.
35. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB (1997). Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Archives of Neurology 54, 836-840.
36. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A (1987). Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. Journal of Clinical Psychiatry 48 (Suppl.), 9-15.
37. Rogers SI, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145.
38. Rosen J, Zubenko GS (1991). Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biological Psychiatry 29, 224-232.
39. Rosen WG, Mohs RC, Davis KL (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry 141, 1356-1364.
40. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ, for the Members of the Alzheimer's Disease Cooperative Study (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine 336, 1216-1222.
41. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH, and the Alzheimer's Disease Cooperative Study (1997a). Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Disease and Associated Disorders 11 (Suppl. 2), S22-S32.
42. Schneider LS, Olin JT, Lyness SA, Chui HC (1997b). Eligibility of Alzheimer's Disease Clinic patients for clinical trials. Journal of the American Geriatrics Society 45, 923-928.
43. Steele C, Rovner B, Chase GA, Folstein M (1990). Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. American Journal of Psychiatry 147, 1049-1051.
44. Stern Y, Albert M, Brandt J, Jacobs DM, Tang M-X, Marder K, Bell K, Sano M, Devanand DP, Bylsma F, Lafleche G (1994). Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 44, 2300-2307.
45. Tabachnick BG, Fidell LS (1989). Using Multivariate Statistics, 2nd ed. New York, Harper & Row.
46. Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner IT, Mueller EA, Murphy DL (1987). L-deprenyl in Alzheimer's disease: preliminary evidence for behavioural change with monoamine oxidase B inhibition. Archives of General Psychiatry 44, 427-433.
47. Tariot PN, Mack JL, Patterson MB, Edland SD, Wiener MF, Fillenbaum G, Blazina L, Ten L, Rubin E, Mortimer JA, Stern Y, and the Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. (1995). The CERAD Behavior Rating Scale for Dementia (BRSD). American Journal of Psychiatry 152, 1349-1357.
48. Teri LL, Logsdon RG (1995). Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. Journal of Geriatric Psychiatry and Neurology 8 (Suppl. 1), S8-S17.
49. Weiner MF, Koss E, Wild KV, Folks DG, Tariot P, Luszczynska H, Whitehouse P (1996). Measures of psychiatric symptoms in Alzheimer patients: a review. Alzheimer Disease and Associated Disorders 10, 20-30.